FDA Drug Recalls

Recalls / Class II

Class IID-0234-2026

Product

OraVerse, (Phentolamine Mesylate) Injection, 0.4 mg/1.7mL, packaged in a carton containing 10 cartridges, 0.4 mg/1.7mL, Rx only, Made in Canada by Novocol Pharmaceutical of Canada, Inc., Distributed by Septodont, Inc., Louisville, Co, 80027, NDC 0362-0101-10

Brand name
Oraverse
Generic name
Phentolamine Mesylate
Active ingredient
Phentolamine Mesylate
Route
Submucosal
NDC
0362-0101
FDA application
NDA022159
Affected lot / code info
Lot: D05004E, expires: 04-30-2027

Why it was recalled

Defective container: cracked/broken cartridges

Recalling firm

Firm
Novocol Pharmaceutical of Canada, Inc.
Manufacturer
Septodont, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
25 Wolseley Crt, Cambridge, N/A, Canada

Distribution

Quantity
1,636 cartons
Distribution pattern
U.S.A. Nationwide

Timeline

Recall initiated
2025-10-31
FDA classified
2025-12-12
Posted by FDA
2025-12-24
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0234-2026. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Oraverse · FDA Drug Recalls